Volume 21

Issue 4

Article 45

2013

Brain abnormalities in HIV and stimulant users: Interventions and
prevention

Follow this and additional works at: https://www.jfda-online.com/journal
Part of the Food Science Commons, Medicinal Chemistry and Pharmaceutics Commons,
Pharmacology Commons, and the Toxicology Commons

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative
Works 4.0 License.
Recommended Citation
Chang, L.; Shoptaw, S.; and Normand, J. (2013) "Brain abnormalities in HIV and stimulant users:
Interventions and prevention," Journal of Food and Drug Analysis: Vol. 21 : Iss. 4 , Article 45.
Available at: https://doi.org/10.1016/j.jfda.2013.09.021

This Conference Paper is brought to you for free and open access by Journal of Food and Drug Analysis. It has
been accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and
Drug Analysis.

j o u r n a l o f f o o d a n d d r u g a n a l y s i s 2 1 ( 2 0 1 3 ) s 7 es 9

Available online at www.sciencedirect.com

ScienceDirect
journal homepage: www.jfda-online.com

Brain abnormalities in HIV and stimulant users:
Interventions and prevention
Linda Chang a,*, Steven Shoptaw b, Jacques Normand c
a

John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
Center for Behavioral and Addiction Medicine, Department of Family Medicine, David Geffen School of Medicine,
University of California, Los Angeles, CA, USA
c
AIDS Research Program, National Institute on Drug Abuse, Bethesda, MD, USA
b

abstract
Keywords:

The session, “HIV and other Infectious Diseases,” was chaired by Dr. Jacques Normand,

Brain abnormalities

Director of the AIDS Research Program of the US National Institute on Drug Abuse. The two

HIV prevention

presenters (and their presentation topics) were: Dr. Linda Chang (“Neural Correlates of

Neurocognitive disorder

Cognitive Deficits and Training Effects on Brain Function in HIV-infected Individuals”) and

Stimulant use

Dr. Steven Shoptaw (“HIV Prevention in Substance Users”).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

In this session, both presenters discussed human immunodeficiency virus (HIV)-related issues among stimulant users,
with Dr. Chang focusing on brain abnormalities among HIVinfected stimulant users and Dr. Shoptaw focusing on HIV
prevention.

2.

Presentations

Dr. Linda Chang is a professor of medicine (neurology) at the
University of Hawaii’s John A. Burns School of Medicine. Dr.
Chang reported that despite effective viral suppression with
antiretroviral medications, approximately 50% of HIVinfected individuals continue to show neurocognitive deficits, especially in working memory and attention. She
demonstrated in her presentation how various multimodal

brain imaging studies can be used to evaluate the neuropathophysiological changes in HIV patients. For example,
proton magnetic resonance spectroscopy (1H MRS) studies
demonstrated elevated myo-inositol levels, but lower levels of
glutamate [1e3], which suggested excess neuroinflammation,
whereas functional magnetic resonance imaging (MRI) studies
showed compensatory changes, as well as lower cognitive
reserve, suggesting premature aging in HIV patients [4]. The
degree of neuroinflammation and lower cognitive reserve
were often related to the severity of cognitive deficits
measured on neuropsychological tests in these HIV-infected
individuals. HIV-infected individuals with the APOEε4 gene,
a major risk factor for Alzheimer’s disease, also showed
greater brain atrophy, and the APOEε4 gene also renders them
particularly vulnerable to cognitive deficits [5]. After using
intensive computerized working-memory training in HIV patients, preliminary data from Dr. Chang’s laboratory show
that these patients may improve their cognitive function and

* Corresponding author. Department of Medicine, John A. Burns School of Medicine, University of Hawaii, 1356 Lusitana Street,
University Tower, 7th Floor, Honolulu, HI 96813, USA.
E-mail address: lchang@hawaii.edu (L. Chang).
1021-9498/$ e see front matter Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. All rights reserved.
http://dx.doi.org/10.1016/j.jfda.2013.09.021

S8

j o u r n a l o f f o o d a n d d r u g a n a l y s i s 2 1 ( 2 0 1 3 ) s 7 es 9

that their functional MRI showed normalization of the
abnormal brain networks after training. Dr. Chang and colleagues further demonstrated that the LXMIA genetic polymorphism also may predict the level of improvement from
working-memory training effects. Ongoing studies will
further evaluate how neuroinflammation may be related to
cognitive function after cognitive training in these HIVinfected individuals.
Dr. Steven Shoptaw is executive director of the UCLA
Center for Behavioral and Addiction Medicine, and professor
in both the Department of Family Medicine and Department of
Psychiatry and Biobehavioral Sciences at UCLA. Dr. Shoptaw’s
talk focused on HIV prevention efforts that have stemmed
new infections among substance users, particularly among
injection drug users, due to the scaling-up of interventions
that target HIV-positive substance users and reduce harm
(syringe exchange programs), provide treatment (opioid substitution therapies), and ensure quality HIV medical care [access to antiretroviral therapy (ART)]. Yet most substances used
around the world are administered via non-injection methods
and there are only a handful of HIV prevention interventions
that target non-injecting substance users at risk for HIV
transmission. HIV incidence rates are high among subgroups
of HIV-negative substance users, including men who have sex
with men (MSM), female sex workers, street youth, and itinerant laborers. Attributable fractions of new infections due
solely to substance use, that would otherwise guide intervention development and implementation, are available only
for MSM substance users. There is existing evidence for using
a combination of HIV prevention strategies in both HIVpositive and HIV-negative substance users. Studies of users
of stimulants and alcohol show ways that drug-dependence
treatment can function as HIV prevention in reductions of
drug use and of concomitant sexual risk behaviors. Structural
interventions (policies for criminal justice and healthcare
settings) may offer cost-effective strategies to reduce HIV
transmission in substance users. Greater detail of this presentation can be found in Shoptaw (2013) in this Special Issue.

3.

Discussion

Several questions were raised and discussed.
(1) Why do most studies on neurocognitive impairments
among HIV patients focus on stimulant use, such as
methamphetamine or cocaine?
First, stimulant drugs are one of the major categories of
drugs abused by this population. Second, like HIV, stimulant
drugs may be neurotoxic to the dopaminergic system, which
in turn may lead to impairments in attention and working
memory. Since attention and working memory are necessary
for almost all cognitive tasks, the additive and synergistic effects of HIV and stimulant drugs have the greatest impact on
neurocognitive deficits in this population.
(2) Have we looked at anti-inflammatory drugs such as
marijuana, to see if they can help reduce adverse effects on
cognitive functioning caused by HIV?

Marijuana use is even more prevalent than stimulant use
in this population. Dr. Chang’s laboratory has started to
examine the effect of marijuana on the immune system
among HIV patients. To her surprise, instead of antiinflammatory effects, they have seen higher levels of peripheral inflammatory markers, such as activated monocytes
(CD14/CD16) in these patients [6]. However, using proton
spectroscopy, they found that while HIV and marijuana users
each showed unique patterns of neurometabolite abnormalities, HIV patients who used marijuana show normalization of
the lower brain glutamate in the frontal white matter, which
indeed suggests less neuroinflammation in that brain region,
but they had even lower glutamate in the striatum, suggesting
greater inflammation or neuronal dysfunction [7]. Therefore,
the peripheral and central effects of marijuana may be
different, and the different brain regions are affected differently. Dr. Chang suspects that when one smokes marijuana, it
is not just tetrahydrocannabinol (THC) that enters the body,
because there are almost 200 other compounds in marijuana.
This may be similar to the observation that nicotine is neuroprotective, but smoking tobacco cigarettes is not healthy for
the lungs or even the brain. Tobacco smoking may not be
neuroprotective for all brain regions, since one is exposed to
more than just nicotine from tobacco smoke.
(3) How big is the impact of their neurocognitive deficits on
everyday life?
The majority of HIV patients in Dr. Chang’s studies are not
able to work because of HIV-associated neurocognitive disorder (HAND). There are a lot of data showing that HAND
severely impacts the functioning of these patients, which
could be due to the fact that the cognitive impairment renders
it difficult for them to manage the demands of a job.
(4) Is it morally and ethically correct to divert ART medications to HIV-negative people for prevention when there is
insufficient coverage of HIV-positive people globally?
The response was that there are different ethics depending
upon the level of resources available to a country. For
instance, in the United States and other developed nations, it
is morally (and perhaps ethically) wrong that there should be
any person living with HIV who is without access to ART. The
question of whether there is available medication is not a
relevant one in developed nations.
(5) Are the measurement and definition of HIV risk behaviors
adequate?
Risky sexual practices (e.g., without condom use) and
needle-sharing may not always increase the risks for HIV
infection or transmission if, say, the persons involved do not
have HIV or only clean needles are used. The constructs of HIV
risky behaviors have not been very precise, and therefore, are
not very useful. Future research should identify biomarkers
that can be more objective and useful.
(6) How do we know if it is HIV that enhances substance
abuse, and not something preexisting?
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It could be that these patients are genetically susceptible to
these problems (i.e., more prone to risk-taking behaviors), and
that is the reason why they start abusing substances or
become addicted. A recent brain imaging study suggests the
possibility of premorbidity in stimulant users of amphetamines, since their non-amphetamine using siblings also
showed the same brain abnormalities [8]. However, in that
study, many of the non-drug using siblings were tobacco
smokers. Since nicotine is a form of stimulant too, and they
had similarly enlarged striatal brain structures to their stimulant abusing siblings, the enlarged striata could have resulted from the stimulant use, rather than the enlargement as a
premorbid phenotype. Therefore, Dr. Chang believes that
longitudinal studies are needed to evaluate the changes over
time in relation to the progression of the disease (e.g., drug use
or HIV infection). Translational research using animal models
that can verify the clinical observation will also be useful to
test the hypotheses.
(7) What is the connection between cognitive enhancement
and drug-use reduction?
While we can clearly enhance cognitive functioning,
enhancing cognition may not cause a reduction in drug use.
Some suggest that the anti-inflammatory and neuroprotective
effects of memantine may help address substance use. Others
suggest that methamphetamine users do many other risky
activities besides using methamphetamine. When methamphetamine is taken out of the person’s activities, something
else needs to replace or fill the void. Therefore, helping patients improve their cognitive functioning so that they can
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engage in normal activities could be a way to prevent methamphetamine use.
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